Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV

NCT02191202 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02191202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02191202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
June 30, 2004
Completion date
Not reported
Enrollment
283 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections